Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Nkgen Biotech Inc NKGN

NKGen Biotech, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapeutics. Its product candidates are based on a manufacturing and cryopreservation process, which produces SuperNK (SNK) cells. SNK cells can be produced in large quantities and cryopreserved, while... see more

NDAQ:NKGN - Post Discussion

Nkgen Biotech Inc > NKGN....early a.m runner on NR....Caveat Emptor imho ; )
View:
Post by Iseneschal on Jul 18, 2024 9:10am

NKGN....early a.m runner on NR....Caveat Emptor imho ; )

Be a chaser and your going to get your face ripped off....P.O set up!!!

https://www.sec.gov/Archives/edgar/data/1845459/000121390024060562/ea0204651-06.htm

Currently $1.25 in the PM opening
Comment by Iseneschal on Jul 18, 2024 10:03am
Can't say I didn't warn you.....now at $1.06 n.l.o.d All the Chasers are roasted again !!!!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities